Status:
COMPLETED
Theranova vs High-flux HD Comparison
Lead Sponsor:
The University of Hong Kong
Collaborating Sponsors:
Baxter Healthcare Corporation
Conditions:
End Stage Renal Failure on Dialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research proposal of an investigator-initiated clinical study aims to examine the impact of uremic toxin removal afforded by middle cut-off (MCO) dialysis on clinical parameters and surrogate bio...
Detailed Description
Accumulation of uremic toxins is associated morbidity and mortality in patients with end-stage renal disease, but the pathogenic mechanisms how they lead to various clinical complications remain elusi...
Eligibility Criteria
Inclusion
- adult patients age greater than 18 years old
- end-stage renal failure on two- or three-times per week high-flux HD for more than 90 days
- mean spKt/Vurea \>1.2 per session (for 3 dialysis sessions per week) or spKt/Vurea \>1.8 per session (for 2 dialysis sessions per week)
Exclusion
- active malignancy
- unable to give informed consent or complete questionnaires
- unstable clinical condition defined as significant clinical event requiring hospitalization in the past 90 days
- unreliable vascular access
- unable to achieve HD blood flow \>150ml/min
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04106310
Start Date
November 1 2019
End Date
June 30 2021
Last Update
September 29 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Nephrology, Department of Medicine, Queen Mary Hospital
Hong Kong, Hong Kong
2
Tung Wah Hospital
Hong Kong, Hong Kong